Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The injectable antiretroviral could potentially be given once every six months for HIV treatment or prevention.
Compared to other common HIV treatments, dolutegravir-based regimens maintained viral suppression even without perfect adherence.
The novel HIV capsid inhibitor also shows promise for previously untreated people.
Lenacapavir shows promise for long-acting HIV treatment and prevention.
A single dose of the HIV capsid inhibitor reduced viral load in highly treatment-experienced people.
People whose viral load rebounds on Tivicay may not need to switch medications.
Resistance to four HIV drug classes is tied to high risk of disease and death.
This finding among sub-Saharan Africans is quite concerning since dolutegravir is now the preferred first-line HIV treatment worldwide.
This finding comes from a small study of people with highly resistant HIV.
Black study participants switched from a regimen with two nucleoside/nucleotide reverse transcriptase inhibitors plus one other HIV drug.
Extended follow-up confirms that the long-acting monoclonal antibody works well for people with highly resistant HIV.
The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.
A handful of such cases have been reported since Truvada was approved as pre-exposure prophylaxis in 2012.
Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.